ATACAND TABLET
País: Canadà
Idioma: anglès
Font: Health Canada
Fitxa tècnica
(SPC)
23-02-2016
Alguns documents d’aquest producte actualment no estan disponibles, podeu enviar una sol·licitud al nostre servei d’atenció al client i us ho notificarem tan bon punt puguem obtenir-los.
Enviar sol.licitud.
Enviar sol.licitud.
ingredients actius:
CANDESARTAN CILEXETIL
Disponible des:
ASTRAZENECA CANADA INC
Codi ATC:
C09CA06
Designació comuna internacional (DCI):
CANDESARTAN
Dosis:
32MG
formulario farmacéutico:
TABLET
Composición:
CANDESARTAN CILEXETIL 32MG
Vía de administración:
ORAL
Unidades en paquete:
30
tipo de receta:
Prescription
Área terapéutica:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Resumen del producto:
Active ingredient group (AIG) number: 0135220004; AHFS:
Estat d'Autorització:
APPROVED
Data d'autorització:
2008-05-29
Fitxa tècnica
COPYRIGHT 1998-2016 ASTRAZENECA CANADA INC.
Page 1 of 39
PRODUCT MONOGRAPH
ATACAND
®
candesartan cilexetil tablets
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AT
1
Receptor Blocker
AstraZeneca Canada Inc.
1004 Middlegate Road
Mississauga, Ontario
L4Y 1M4
www.astrazeneca.ca
Date of Revision:
February 19, 2016
Submission Control Number: 187873
ATACAND
®
is a registered trademark of the AstraZeneca group of companies.
Manufactured
under license from Takeda Pharmaceutical Company Ltd.
COPYRIGHT 1998-2016 ASTRAZENECA CANADA INC.
Page 2 of 39
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
......................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
.................................................................................................
4
WARNINGS AND PRECAUTIONS
...............................................................................
5
ADVERSE REACTIONS
.................................................................................................
9
DRUG INTERACTIONS
...............................................................................................
15
DOSAGE AND ADMINISTRATION
...........................................................................
19
OVERDOSAGE
..............................................................................................................
22
ACTION AND CLINICAL PHARMACOLOGY
.......................................................... 22
STORAGE AND STABILITY
.......................................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................... 25
PART II: SCIENTIFIC INFORMATION
.............................................................................
26
PHARMACEUTICAL INFORMATION
.......................................................
Llegiu el document complet
